{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:14:50Z","timestamp":1788261290429,"version":"build-2803163510"},"reference-count":64,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14728214.2026.2705211","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:03:04Z","timestamp":1784120584000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas"],"prefix":"10.1080","volume":"31","author":[{"given":"Jane E.","family":"Rogers","sequence":"first","affiliation":[{"name":"U.T. M.D. Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Horak","sequence":"additional","affiliation":[{"name":"U.T. M.D. Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Kroll","sequence":"additional","affiliation":[{"name":"U.T.M.D. Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[{"name":"U.T. M.D. Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"National Comprehensive Cancer Network. Gastric cancer. Version 2. 2025 [cited 2025 Jul 15]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"},{"key":"e_1_3_4_4_1","unstructured":"World Cancer Research Fund. Stomach cancer statistics. [cited 2025 Jul 15]. Available from: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/stomach-cancer-statistics"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_398068"},{"key":"e_1_3_4_6_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer stat facts: stomach cancer. [cited 2025 Jul 15]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100056"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205105"},{"key":"e_1_3_4_9_1","unstructured":"Trastuzumab (herceptin) prescribing information. [cited 2025 Jul 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1998\/trasgen092598lb.pdf"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411403"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1791"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01335-4"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.6598"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6136"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"e_1_3_4_16_1","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. [cited 2025 Jul 16]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408121"},{"key":"e_1_3_4_20_1","unstructured":"U.S. Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas. Accessed 7\/16\/2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00575"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119"},{"key":"e_1_3_4_24_1","unstructured":"Daiichi Sankyo Inc. Study of TDXd chemotherapy pembrolizumab and trastuzumab in first-line metastatic HER2-positie gastric or gastroesophageal junction cancer. ClinicalTrials.gov. NLM Identifier: NCT06731478. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06731478"},{"key":"e_1_3_4_25_1","unstructured":"AstraZeneca. A phase III study of rilvegostomig in combination with fluropyrimidine and trastuzumab deruxtecan as the first-line treatment for HER2-positive gastric cancer. ClinicalTrials.gov NLM Identifier: NCT06764875.Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06764875"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.156"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4206"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30408"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4025"},{"key":"e_1_3_4_31_1","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2 positive biliary tract cancer. [accessed 2025 Jul 16]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.164"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00287-6"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01614-x"},{"key":"e_1_3_4_37_1","unstructured":"RemeGen Co. Ltd. A study of disitamab vedotin combined with tislelizumab and chemotherapy versus tislelizumab combined with chemotherapy in HER2-low advanced gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov NLM Identifier: NCT06944496. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06944496"},{"key":"e_1_3_4_38_1","unstructured":"RemeGen Co. Ltd. DV combined with cadonilimab in subjects with HER2-expressing gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy. ClinicalTrials.gov NCT06221748. NLM Identifier: NCT06221748.Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4012"},{"key":"e_1_3_4_40_1","unstructured":"The First Affiliated Hospital of Zhengshou University. RC48 plus AK104 as first-line treatment for HER2-overexpressing advanced gastric cancer. ClinicalTrials.gov NLM Identifier: NCT06492317. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06492317"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1007"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100563"},{"key":"e_1_3_4_43_1","unstructured":"MacroGenics. Combination margetuximab retifanlimab tebotelimab and chemotherapy phase 2\/3 trial in HER2+ gastric\/GEJ cancer (MAHOGANY. ClinicalTrials.gov. NLM Identifier: NCT04082364. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04082364"},{"key":"e_1_3_4_44_1","unstructured":"Shanghai Henlius Biotech. A phase III clinical study of HLX22 in combination with trastuzumab and chemotherapy for the treatment of gastroesophageal junction and gastric cancer. ClinicalTrials.gov. NLM Identifier: NCT06532006.Available from: https:\/\/clinicaltrials.gov\/study\/NCT06532006"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.06.004"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.589"},{"key":"e_1_3_4_47_1","unstructured":"Biotech. Zymeworks halts plans for phase 2 ADC trial to mull \u2018evolving clinical landscape. [cited 2026 Apr 28]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/zymeworks-halts-plans-phase-2-adc-trial-mull-evolving-clinical-landscape"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100814"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04246-x"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102284"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-025-01300-0"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103391"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071336"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i15.1964"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0464"},{"key":"e_1_3_4_56_1","unstructured":"Reveal Genomics. ASCO 2025: reveal genomics unveils new her2dx data from 800+ patients. [cited 2025 Jul 16]. Available from: https:\/\/www.reveal-genomics.com\/press-releases\/asco-2025-reveal-genomics-unveils-new-her2dx-data-from-800-patients"},{"key":"e_1_3_4_57_1","unstructured":"MedRxIV; Sheng T Sundar R Srivastava S et al. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to trastuzumab and trastuzumab deruxtecan. [cited 2025 Jul 16]. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2024.10.29.24316248v1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162854"},{"issue":"12","key":"e_1_3_4_59_1","first-page":"175883592093788","article-title":"A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction\/gastric cancer trastuzumab resistant: the FiGhTeR trial","volume":"7","author":"Merz V","year":"2020","unstructured":"Merz V, Zecchetto C, Simionato F, et al. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction\/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol. 2020;7(12):1758835920937889.","journal-title":"Ther Adv Med Oncol"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101792"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1324"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz247.133"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103679"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0302"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5236"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1412709"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2705211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14728214.2026.2705211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2705211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:23:12Z","timestamp":1788258192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2705211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14728214.2026.2705211"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2705211","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}